NK
☆    

India,
2024-04-30 06:33
(47 d 23:39 ago)

Posting: # 23966
Views: 562
 

 Orlistat PD Endpoint BE study [Regulatives / Guidelines]

Dear All,

As per the USFDA recommendation, if we conduct the Orlistat PD Endpoint BE study, we may have data (fecal fat) for Baseline, Test, Ref1 and Ref2

Can anyone explain how to analyze the pharmacodynamic study data step by step? how to establish dose response relationship?. Any example dataset are available?

Kindly suggest, which software (WinNonlin/SAS/etc…) is required to analyze these data.

Regards
NK
UA Flag
Activity
 Admin contact
23,057 posts in 4,840 threads, 1,641 registered users;
158 visitors (0 registered, 158 guests [including 84 identified bots]).
Forum time: 06:13 CEST (Europe/Vienna)

If you tell the truth you don’t have to remember anything.    Mark Twain

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5